ClinicalTrials.gg
RecruitingNCT07630545Updated Oct 20, 2026

A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

A Phase 1 interventional study of MTX325 and Placebo in Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease and Early Stage Parkinson's Disease, sponsored by Mission Therapeutics. Recruiting at 18 sites in 4 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Mission Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Nov 2023, registered May 2026).
  • Started Nov 2023; still recruiting 2 years 11 months later.
Updated Oct 20, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.

Planned enrollment
80th of 183
106 · median 80
Started
2023
with 19 others
Phase 1
26 of 246
2 open now
Primary completion
2027-06
later than 36 of 65 live
Registered
237th of 246
by date

Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 80th largest by planned enrollment of the 183 interventional ones that give a count, is one of 20 that started in 2023, is one of 26 in phase 1, reaches primary completion later than 36 of the 65 other live ones, and was the 237th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Parkinson Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.

03

Conditions studied

  • Parkinson's Disease (PD)
  • Mild to Moderate Parkinson's Disease
  • Early Stage Parkinson's Disease

Keywords

  • Parkinson's disease
  • MDS-UPDRS
  • CSF
  • Plasma
  • Biomarkers
  • Mild
  • Moderate
  • Hoehn and Yahr scale
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

PART 5 - Currently recruiting in Parkinson's Disease Patients

Inclusion Criteria

  1. Male and female participants aged ≥ 40 to ≤ 75 years.
  2. Male or female participants. Female participants of must be willing to use highly effective forms of (refer to Section 9.7.1 for details on highly effective methods of contraception and definitions of women of childbearing potential and of fertile men):
  3. (BMI) between 18 and 34.0 kg/m2, inclusive.
  4. If being treated with selective serotonin reuptake inhibitors (SSRIs) for anxiety/ depression, must be on a stable dose for 60 days prior to Day -1 and must remain on that dose for the remainder of the study.
  5. Must have had other causes of Parkinsonism excluded
  6. No history of previous allergy/ sensitivity to MTX325 or any of the contained within the IMP.
  7. Participant with a negative urinary drugs of abuse (DOA) screen (excluding alcohol).
  8. Participant with negative (HIV), surface antigen [HbsAg]) and virus antibody (HCV Ab) test results at Screening.
  9. No history of torsade de pointes or long syndrome and no heart failure, hypokalaemia, or any other additional cardiac risk factors if judged clinically significant in the opinion of the Investigator.
  10. No clinically significant abnormalities in vital signs during the screening period.
  11. Able to perform all protocol assessments and comply with the study visit schedule.
  12. Able and willing to provide .
  13. Clinically established PD as per MDS Criteria[
  14. Absence of dementia as shown by a baseline (MoCA®)

Exclusion Criteria

  1. A clinically significant history of gastrointestinal disorders or any significant medical conditions that would be likely to influence IMP absorption, or evidence of clinically significant central nervous system, respiratory, cardiovascular or metabolic dysfunction or other significant medical conditions with potential to impact participant safety or hinder interpretation of study results.
  2. Clinically significant neurologic disorder other than PD, including history of stroke within 12 months of Screening, seizure within 5 years of Screening, or head trauma with loss of consciousness within 6 months of Screening.
  3. Those with known PD risk genes (per medical history).
  4. Reside in a nursing home or assisted care facility.
  5. No more than 2 PD related freezing episodes or falls in the past 6 months.
  6. Any condition that may predispose participant to complications or technical difficulty with lumbar puncture, in the opinion of the Investigator.
  7. Participants who have conditions that would preclude a lumbar puncture (LP), such as a local infection at the site
  8. Participant who has a history of clinically significant to local anaesthesia, or its derivatives used during CSF collection or to any medication used to prepare the area of LP.
  9. Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS©]
  10. Participants should not be in receipt of any known MATE2k substrates
  11. Plan to receive or administration of rotigotine, catechol-o-methyltransferase (COMT) inhibitors (e.g., entacapone, tolcapone or opicapone), neuroleptics, venlafaxine, NMN, nicotinamide riboside or non-selective Monoamine oxidase [MAO] inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose and during the study conduct.
  12. Clinically significant abnormal test results for serum biochemistry, haematology, coagulation and/or urine analyses as determined within 45 days before first dose of IMP.
  13. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
  14. Participant has any condition that, in the opinion of the investigator, is clinically significant and may put the participant at greater safety risk, influence response to study product, or interfere with study assessment.
  15. Inability to communicate well with the Investigators.
  16. Participation (dosed) in a NCE clinical study within the previous 3 months or five half lives
  17. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
  18. Female participants who are pregnant, breastfeeding or lactating.
  19. Clinically significant abnormalities in 12-lead (ECG)
  20. Participants with recent COVID-19 infection without resolution of symptoms
  21. Participants who have received a COVID-19 vaccine injection from the Screening visit up to first dose of IMP
  22. A clinically significant history of drug or alcohol abuse within the past 2 years.
  23. Currently prescribed treatment for Parkinson's Disease symptoms.
  24. Any history of allergy/atopy including drug-induced allergy history of severe cutaneous adverse reaction or other type 4/delayed-type hypersensitivity.
  25. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.
  26. Previous history of Erythema Multiforme and/or identified current risk factor(s) for Erythema Multiforme
  27. Participant has any to PET or MRI as determined by screening procedures and PET and MRI safety questionnaires as conducted by the site.
  28. Clinically significant history of previous allergy/ sensitivity to [18F] FDG.
  29. Participants who have had previous exposure to ionizing radiation
  30. Chronic kidney disease defined as (GFR) 1.5 × the (ULN) or or AST >3 × ULN or if participant has Class C cirrhosis or equivalent severe hepatic impairment.
  31. Hepatic disease or altered liver function as defined by total >1.5 × the upper limit of normal (ULN) or ALT or AST >3 × ULN or if participant has Child-Pugh Class C cirrhosis or equivalent severe hepatic impairment.
  32. Patients with uncontrolled type I or type II diabetes (insulin or non-insulin dependent).
  33. Current symptomatic Hay fever or any history of hay fever involving more than nose and eyes.

PART 1, 2 ,4 - COMPLETED

Inclusion Criteria:

  1. Healthy male and female (Part 1-2 only) participant, aged ≥ 18 to ≤ 55 years.
  2. Female participant of childbearing potential (Part 1-2 only)
  3. Female participant of non-childbearing potential (Part 1-2 only).
  4. Female participant (Part 1-2 only) with a negative pregnancy test at Screening visit.
  5. Female participant of menopausal status (Part 1-2 only) confirmed by demonstrating at Screening that the serum level of the follicle stimulating hormone (FSH) falls within the respective pathology reference range.
  6. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception
  7. Participant with a body weight of at least 50.0 kg and body mass index (BMI) of 1832 kg/m2. BMI = body weight (kg) / [height (m)]2.
  8. No clinically significant history of previous allergy / sensitivity to MTX325 or any of the excipients contained within the IMP.
  9. No clinically significant abnormal test results for serum biochemistry, haematology, coagulation
  10. Participant with a negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 35 days (45 days Part 4 only) before first dose of IMP.
  11. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen [HbsAg]) and hepatitis C virus antibody (HCV Ab) test results at Screening.
  12. No clinically significant abnormalities in 12-lead electrocardiogram (ECG)
  13. No clinically significant abnormalities in vital signs
  14. Participant must be available to complete the study (including all follow-up visits).
  15. Participant must satisfy an Investigator about his/her fitness to participate in the study.
  16. Participant must provide written informed consent to participate in the study.
  17. Participants with a negative COVID-19 test on admission (if required).
  18. Part 4 only: Participant with normal MRI performed within 3 months of dosing, as judged by the investigator.

Part 4 - COMPLETED

  1. Participants who have had previous exposure to ionizing radiation from research studies
  2. Participant has any contraindication to arterial line insertion
  3. Inability to lie supine for up to 120 mins for PET procedures.
  4. Participant has any contra-indication to MRI as determined by screening procedures and MRI safety questionnaire
  5. Participant suffers from claustrophobia or needle phobia.
  6. Any history of allergy/atopy including drug-induced allergy or any history of severe cutaneous adverse reaction or other type 4/delayed-type hypersensitivity.
  7. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.
  8. Previous history of Erythema Multiforme and/or identified current risk factor(s) for Erythema

Part 3 - COMPLETED

  1. Healthy male and female participant, ≥ 65 years of age.
  2. Female participant of non-childbearing potential.
  3. Female participant of menopausal status confirmed by demonstrating at Screening that the serum level of the follicle stimulating hormone (FSH) falls within the respective pathology reference range.
  4. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception
  5. Participant with a body weight of at least 50.0 kg and BMI of 18-32 kg/m2.
  6. No clinically significant history of previous allergy / sensitivity to MTX325 or any of the excipients contained within the IMP.
  7. No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses determined within 35 days before first dose of IMP.
  8. Participant with an estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation >60 mL/min/1.73 m2.
  9. Participant with a negative urinary drugs of abuse (DOA)
  10. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen [HbsAg]) and hepatitis C virus antibody (HCV Ab) test results at Screening.
  11. No clinically significant abnormalities in 12-lead electrocardiogram (ECG)
  12. No clinically significant abnormalities in vital signs
  13. Participant must be available to complete the study (including all follow-up visits).
  14. Participant must satisfy an Investigator about his/her fitness to participate in the study.
  15. Participant must provide written informed consent to participate in the study.

Exclusion Criteria (Part 1, 2, 4) - COMPLETED

  1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
  2. Use of prescription or non-prescription drugs, excluding allowable drugs and contraception
  3. Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS©] him/herself or others - Part 2 only.
  4. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  5. A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units
  6. Inability to communicate well with the Investigators
  7. Participation (dosed) in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives
  8. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
  9. Vegans, vegetarians or other dietary restrictions (Part 1 food effect evaluation, only).
  10. Users of nicotine products
  11. Participants with an excessive habitual daily intake of caffeine
  12. Female participants who are pregnant, breastfeeding or lactating (Part 1-2 only).
  13. Participants with veins unsuitable for venepuncture and cannulation.
  14. Participants with recent COVID-19 infection without resolution of symptoms
  15. Participants who have received a COVID-19 vaccine injection

Part 1 Treatment Period 2a (CSF sampling) Cohort(s) only:

  1. Participants who have criteria that would preclude a lumbar puncture (LP)
  2. Participant who has a history of clinically significant hypersensitivity to local anaesthesia
  3. Participant who has a history of clinically significant or major back pathology (lumbar) surgery

Part 4 - COMPLETED

  1. Participants who have had previous exposure to ionizing radiation from research studies, such that, in combination with the exposure from this study, their exposure will be >10 mSv for the previous 12 months.
  2. Participant has any contraindication to arterial line insertion
  3. Inability to lie supine for up to 120 mins for PET procedures.
  4. Participant has any contra-indication to MRI
  5. Participant suffers from claustrophobia or needle phobia.
  6. Any history of allergy/atopy
  7. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.
  8. Previous history of Erythema Multiforme and/or identified current risk factor(s) for Erythema Multiforme

Part 3 - COMPLETED

  1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
  2. Evidence of febrile illness within 1 week of first dose of IMP.
  3. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements or any medication known to prolong the QT/QTc interval within 35 days or 5 half-lives
  4. Evidence of clinically significant renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  5. History of torsade de pointes, heart failure, hypokalaemia, long QT syndrome or any other additional cardiac risk factors.
  6. A clinically significant history of drug or alcohol abuse
  7. Participants with an excess habitual daily intake of caffeine
  8. Inability to communicate well with the Investigators
  9. Participation in a NCE clinical study within the previous 3 months or five half-lives
  10. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
  11. Participants who have received a COVID-19 vaccine injection within 35 days prior to first dose of IMP.
  12. Users of nicotine products
  13. Participants with veins unsuitable for venepuncture and cannulation.
  14. Participants with recent COVID-19 infection with resolution of symptoms
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Active comparator
    Parts 1 - 4

    MTX325 Active Oral Capsules - 1.5mg - 100mg These 4 parts are SAD, MAD, Elderly and PET biodistribution.

    Drug: MTX325

  • Placebo comparator
    Parts 1 - 3, and 5

    MTX325 Placebo Capsules - 50mg. Parts 1-3 are SAD, MAD and Elderly cohorts. Matched strength placebo capsules in Part 5 (PD participants)

    Other: Placebo

  • Active comparator
    Part 4

    MTX325 Capsules - 20mg. Radiolabelled MTX325 solution for injection. This is a healthy volunteer PET study. Not placebo controlled.

    Drug: MTX325

  • Active comparator
    Part 5

    MTX325 - 20 mg Capsules

    Drug: MTX325

Interventions

  • DrugMTX325

    MTX325

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    To assess the safety and tolerability of single ascending doses of MTX325, when administered to participants. Adverse Events will be collected. The following vital signs will be measured to form the safety and tolerability outcome- blood pressure, heart rate, oral body temperature, respiratory rate. Laboratory Safety analyses will include biochemistry, haematology, and urinalysis. 12-lead ECG will be performed to collect heart rate, RR interval, PR interval, QRS width, QT interval, and QTcF interval. All participants who receive at least 1 dose of IMP will be included in the safety analysis.

    Time frame: up to 28 days post dose

  2. Brain Biodistribution

    To investigate the brain biodistribution in MTX325. This part of the protocol is intended to ascertain the biodistribution of MTX325 in the brain. Radiolabelled MTX325 will be injected and PET images taken to determine the whole brain and regions of interest distribution volume. MRI images will be performed to be able to co-register regions of interest.

    Time frame: MRI performed during screening period and PET performed on Day 1

  3. Safety and Tolerability

    To evaluate the safety and tolerability of MTX325 in untreated participants with mild to moderate idiopathic PD. Adverse Events will be collected. The following vital signs will be measured to form the safety and tolerability outcome - blood pressure, heart rate, oral body temperature, respiratory rate. Laboratory Safety analyses will include biochemistry, haematology, and urinalysis. 12-lead ECG will be performed to collect heart rate, RR interval, PR interval, QRS width, QT interval, and QTcF interval. All participants who receive at least 1 dose of IMP will be included in the safety analysis.

    Time frame: up to 28 days post dose

07

Study locations

9 of 18 sites recruiting
  • The Royal Adelaide Hospital
    Adelaide, Australia
    Not yet recruiting
    • Thomas E Kimber, Professor · Principal investigator
  • Doherty Clinical Trials
    Melbourne, Australia
    Recruiting
    • Thomas Frisby, Dr · Principal investigator
  • Monash Health, Kingston Centre
    Melbourne, Australia
    Not yet recruiting
    • Niro Vijiaratnam, Dr · Principal investigator
  • Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon
    Lille, France
    Recruiting
    • Prof David Davos, Professor · Principal investigator
  • Hôpital Henri-Mondor (Créteil, AP-HP), Paris
    Paris, France
    Not yet recruiting
    • Philippe Remy, Dr · Principal investigator
  • Pitie-Salpetriere Hospital, Paris
    Paris, France
    Recruiting
    • Louise-Laure Mariani, Professor · Principal investigator
  • Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse
    Toulouse, France
    Not yet recruiting
    • Olivier Rascol, Professor · Principal investigator
  • Technische Universitaet Dresden, Dresden
    Dresden, Germany
    Not yet recruiting
    • Bjoern Falkenburger, Dr · Principal investigator
  • Cambridge Biomedical Research Centre, Cambridge
    Cambridge, United Kingdom
    Recruiting
    • Caroline Williams-Gray, Dr · Principal investigator
  • Neuroclnx, Glasgow
    Glasgow, United Kingdom
    Not yet recruiting
    • David Anderson, Dr · Principal investigator
  • Royal Liverpool University Hospital
    Liverpool, United Kingdom
    Recruiting
    • Antonella Macherello, Dr · Principal investigator
  • Parexel
    London, United Kingdom
    Completed

    Not enrolling at this site.

  • Perceptive
    London, United Kingdom
    Completed

    Not enrolling at this site.

  • Simbec-Orion
    Merthyr Tydfil, United Kingdom
    Completed

    Not enrolling at this site.

  • Freeman Hospital, Newcastle Upon Tyne
    Newcastle, United Kingdom
    Recruiting
    • Dr David Ledingham, Dr · Principal investigator
  • University Hospitals Plymouth NHS Trust, Derriford Hospital
    Plymouth, United Kingdom
    Recruiting
    • Stephen Mullin, Dr · Principal investigator
  • Salford Hospital (Manchester)
    Salford, United Kingdom
    Recruiting
    • Monty Silverdale, Professor · Principal investigator
  • Southampton General Hospital, Southampton
    Southampton, United Kingdom
    Recruiting
    • Boyd Ghosh, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jun 2027, 43 months after the start.

Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 43 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
Jun 5, 2026
StartActual
Nov 30, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 27, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Pitie-Salpetriere Hospital, Paris is now Recruiting
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Pitie-Salpetriere Hospital, Paris is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07630545
Lead sponsor
Mission Therapeutics
Collaborators
Michael J. Fox Foundation for Parkinson's Research, Parkinson's UK
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Nov 30, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 27, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Sarah J Fritchley, PhD
Contact
sfritchley@missiontherapeutics.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion